Last reviewed · How we verify
Arm B: FOLFIRI or FOLFOX
FOLFIRI and FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluorouracil-based cytotoxic activity, with irinotecan targeting topoisomerase I or oxaliplatin targeting DNA cross-linking.
FOLFIRI and FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluorouracil-based cytotoxic activity, with irinotecan targeting topoisomerase I or oxaliplatin targeting DNA cross-linking. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer.
At a glance
| Generic name | Arm B: FOLFIRI or FOLFOX |
|---|---|
| Also known as | Arm C: FOLFIRI or FOLFOX |
| Sponsor | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
| Drug class | Combination chemotherapy regimen |
| Target | DNA (topoisomerase I for irinotecan; DNA cross-linking for oxaliplatin; thymidylate synthase for 5-FU) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFIRI combines fluorouracil (5-FU), leucovorin, and irinotecan (a topoisomerase I inhibitor that prevents DNA unwinding and repair). FOLFOX combines fluorouracil, leucovorin, and oxaliplatin (a platinum agent causing DNA cross-links). Both regimens are standard chemotherapy backbones for colorectal cancer that work through distinct mechanisms of DNA damage and inhibition of nucleotide synthesis.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Anemia
- Mucositis
- Peripheral neuropathy (oxaliplatin)
- Fatigue
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers (PHASE1)
- Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (PHASE3)
- Intensified Chemotherapy in CRC After Resection of Liver Metastases (PHASE2, PHASE3)
- Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer (PHASE3)
- Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer (PHASE2)
- Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: